Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDO2 | P48775 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CYP2E1 | P05181 | 2/20 | 0.47 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | CYP4B1 | P13584 | 2/20 | 0.47 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.47 |
| ▸ | CYP3A5 | P20815 | 2/20 | 0.47 |
| ▸ | CYP2A7 | P20853 | 2/20 | 0.47 |
| ▸ | CYP3A7 | P24462 | 2/20 | 0.47 |
| ▸ | CYP2F1 | P24903 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30785681 | 0.87 | TDO2 (0.55) | TDO2CYP3A4ALDH1A1ADORA2AADORA1 | |
| SCHEMBL396757 | 0.87 | TDO2 (0.55) | TDO2CYP3A4ALDH1A1ADORA2AADORA1 | |
| SCHEMBL28184418 | 0.84 | CYP3A4 (0.54) | TDO2CYP3A4ALDH1A1ADORA2AADORA1 | |
| SCHEMBL29132921 | 0.83 | TDO2 (0.51) | TDO2CYP3A4ALDH1A1ADORA2AADORA1 | |
| Hydrochloric Acid SCHEMBL31425163 | 0.83 | CYP3A4 (0.53) | TDO2CYP3A4ALDH1A1ADORA2AADORA1 | |
| SCHEMBL3491387 | 0.81 | ABL1 (0.52) | CYP3A4ALDH1A1KDM4EKMT2AMAPT | |
| SCHEMBL9003875 | 0.81 | TDO2 (0.50) | TDO2CYP3A4ALDH1A1ADORA2AADORA1 | |
| SCHEMBL2020140 | 0.81 | ABL1 (0.59) | TDO2CYP3A4ALDH1A1ADORA2AADORA1 | |
| SCHEMBL18439119 | 0.80 | TDO2 (0.56) | TDO2CYP3A4ALDH1A1ADORA2AADORA1 | |
| SCHEMBL17556326 | 0.80 | ABL1 (0.44) | TDO2CYP3A4ALDH1A1CYP1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10392383-B2 | 3-(1H-benzo[d]imidazol-2-yl)-1H-pyrazolo[4,3-b]pyridines and therapeutic uses thereof | SAMUMED, LLC (US) | 2019-08-27 | — | — | US | disclosed |
| US-10392383-B2 | 3-(1H-benzo[d]imidazol-2-yl)-1H-pyrazolo[4,3-b]pyridines and therapeutic uses thereof | SAMUMED, LLC (US) | 2019-08-27 | — | — | US | disclosed |
| WO-2017023989-A1 | 3-(1H-BENZO[D]IMIDAZOL-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF | SAMUMED, LLC. (US) | 2017-02-09 | — | — | WO | disclosed |
| WO-2017023989-A1 | 3-(1H-BENZO[D]IMIDAZOL-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF | SAMUMED, LLC. (US) | 2017-02-09 | — | — | WO | disclosed |
| US-20100093748-A1 | SUBSTITUTED PIPERIDINES HAVING PROTEIN KINASE INHIBITING ACTIVITY | ASTEX THERAPEUTICS LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
| US-20100093748-A1 | SUBSTITUTED PIPERIDINES HAVING PROTEIN KINASE INHIBITING ACTIVITY | ASTEX THERAPEUTICS LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
| US-20100093748-A1 | SUBSTITUTED PIPERIDINES HAVING PROTEIN KINASE INHIBITING ACTIVITY | ASTEX THERAPEUTICS LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
| WO-2008075109-A1 | SUBSTITUTED PIPERIDINES HAVING PROTEIN KINASE INHIBITING ACTIVITY | ASTEX THERAPEUTICS LIMITED (GB) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10392383-B2 | 3-(1H-benzo[d]imidazol-2-yl)-1H-pyrazolo[4,3-b]pyridines and therapeutic uses thereof | WNT1, WNT3, WNT3A | TDO2 1718/4885CYP3A4 1800/4885ALDH1A1 817/4885 |
| US-20100093748-A1 | SUBSTITUTED PIPERIDINES HAVING PROTEIN KINASE INHIBITING ACTIVITY | PRKAR2B, GRK3, PRKAR2A | TDO2 3314/4885CYP3A4 3708/4885ALDH1A1 4612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.